News

Filter

FDA panel backs J&J diabetes drug Invokana (canagliflozin)

11-01-2013

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

canagliflozinDiabetesInvokanaJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021

16-10-2012

The type 2 diabetes drug market will nearly double over the next decade, increasing from $26 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesJanuviaJohnson & JohnsonMarkets & MarketingMerck & CoPharmaceutical

Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA

27-06-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag International…

Anti-viralscanagliflozinDiabetesEgriftaEuropeFerrer InternacionalJanssenJohnson & JohnsonPharmaceuticalRegulation

Janssen files NDA with FDA for canagliflozin in type 2 diabetes

01-06-2012

Janssen Research & Development, a subsidiary of health care giant Johnson & Johnson (NYSE: JNJ) has submitted…

canagliflozinDermatologicalsJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Russia’s type 2 diabetes drug market will grow to $1.7 billion in 2015

13-10-2011

Russia’s type 2 diabetes drug market will grow more than seven percent annually from $1.2 billion…

AstraZenecaBristol-Myers SquibbcanagliflozindapagliflozinDiabetesEuropeJohnson & JohnsonMarkets & MarketingPharmaceutical

Back to top